Dermatitis, Atopic, Dermatitis Eczema, Pruritus
Conditions
Brief summary
This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects
Detailed description
This is a two part, randomized, blinded, vehicle-controlled study to determine a safe and tolerable dose of ASN008 TG. Part A will asses a single ascending dose of ASN008 TG in cohorts of healthy volunteers, while Part B will assess multiple ascending doses of TG, to be determined (TBD) based on Part A safety and tolerability, in patients with mild-to-moderate dermatitis. Results from Part A and B will characterize safety, tolerability and pharmacokinetics. Part B patients will be assessed for changes in pruritus based on a numerical rating scale (NRS) of pruritus at baseline and on Day 15.
Interventions
DRUGASN008 TG
ASN008 TG
DRUGPlacebo TG
Placebo TG
Sponsors
Asana BioSciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Part A: Double blinded, with exception of unblinded dispensing pharmacist Part B: Double blinded
Intervention model description
Phase 1, multicenter, double-blind, vehicle-controlled, randomized ascending doses trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Part A - Healthy Volunteers: * Written informed consent obtained prior to any required study-related procedure * Healthy female or male subject aged 18 to 65 * Willing to use medically effective methods of birth control * Females of reproductive potential must have a negative serum pregnancy test at screening and negative serum or urine pregnancy test prior to first study drug application on Day 1 * Non-smoker (no nicotine products for at least 6 months prior to screening) * BMI ≥18.5 kg/m2 and ≤32.0 kg/m2 with minimum weight of 60 kg Part B- Subjects with AD: * Written informed consent obtained prior to any required study-related procedure * Confirmed diagnosis of active atopic dermatitis (AD) * History of AD for at least 6 months prior to Day 1 with an investigator global assessment ≥3 and body surface area covered with 1-10% AD * Pruritus score (NRS)≥ 5 at screening and NRS ≥7 on Day 1
Exclusion criteria
Both Part A and Part B: * Pregnant or breast-feeding women * Skin disease that may interfere with study assessments * Febrile illness within 6 days prior to Day 1, history of cancer within 5 years of Day 1, major surgery within 8 weeks prior to Day1, known immunodeficiencies, positive for hepatitis B or C or HIV infection * Significant medical/surgical history or condition or current physical/laboratory/ECG/ vitals signs abnormality that might compromise the subject * Corrected QT duration ≥450 milliseconds or other significant ECG abnormality * Received marketed or investigational biological agent within 12 weeks prior to Day 1 or JAK inhibitor or nonbiological product or device within 4 weeks of Day 1 or within 8 weeks of Day 1 if investigational product used or any drug/ substance that is a strong inhibitor or inducer of CYP3A4 or CYP2D6 * Suspected hypersensitivity/allergy to lidocaine * Significant drug or alcohol abuse or mental illness in 2 years prior to Day 1 Part A Only- Healthy Volunteers: -Used medications or skin emollients within 2 weeks prior to Day 1 unless approved by investigator and sponsor Part B Only - Subjects with AD: * Has infected atopic dermatitis * Used dupilumab 12 weeks prior to Day 1 * Used doxepin, hydroxyzine or diphenhydramine, urea containing topical products within 1 week prior to Day 1 * Used systemic antibiotics or topical medicated treatment or other systemic treatments that could affect AD 2 weeks prior to Day 1 * Received any UV-B phototherapy, excimer laser treatment or psoralen-UV-A treatment within 4 weeks prior to Day 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate safety and tolerability of ASN008 topical gel to define a maximum tolerated dose (Part A and B) | Part A: 14 days; Part B: 22 days | Analyze incidence of treatment-emergent adverse events (TEAE) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Calculate the Pharmacokinetic Half-life (Part A and B) | 7 days and 16 days | Derive maximum blood plasma concentration of Time required for ASN008 concentration to decrease by 50% |
| Calculate the Pharmacokinetic maximum concentration (Part A and B) | 7 days and 16 days | Maximum concentration of ASN008 achieved after dosing |
| Calculate area under the plasma concentration versus time curve (Part A and B) | 7 days and 16 days | A plot of the concentration of ASN008 in plasma over time |
| Change from baseline in Eczema Area and Severity Score (EASI) in AD subjects (Part B) | 22 days | Measurement of area and severity of atopic dermatitis based on composite score 0 to 72 encompassing degree of erythema, induration, excoriation and lichenification; each scored from 0 to 3 with 0 indicating none and 3 indicating severe |
| Change from baseline in Investigator Global Assessment Score in AD subjects (Part B) | 22 Days | 5 point morphological assessment of overall disease severity scored from 0 to 4 with 0 indicating clear (no inflammation) and 4 indicating severe (marked erythema) |
| Change from baseline in pruritus NRS in AD subjects (Part B) | 22 days | Numeric Rating Scale ranging from 0 to 10; 0 indicates no itching; 10 indicates worst possible itching; Rating of pruritis based degree, duration, direction, disability, and distribution |
Countries
Canada, United States
Outcome results
None listed